Welcome to our dedicated page for Iqvia Hldgs SEC filings (Ticker: IQV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The IQVIA Holdings Inc. (NYSE: IQV) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including current reports on Form 8-K and other documents filed with the U.S. Securities and Exchange Commission. IQVIA’s filings confirm that its common stock is registered under Section 12(b) of the Securities Exchange Act of 1934 and trades on the New York Stock Exchange under the symbol IQV.
IQVIA uses Form 8-K to report material events such as quarterly financial results, amendments to its credit agreements and leadership or board changes. For example, the company has filed 8-K reports describing financial results for specific quarters, an amendment to its Fifth Amended and Restated Credit Agreement and the planned transition of its chief financial officer. Other 8-K filings cover the appointment of new directors and related governance matters.
For investors analyzing IQVIA, these filings help explain the company’s financial condition, capital structure and key corporate developments. They also provide context for IQVIA’s role as a global provider of clinical research services, commercial insights and healthcare intelligence, including how it finances its operations and manages governance and leadership transitions.
On Stock Titan, SEC filings for IQVIA are updated as new documents are posted to the SEC’s EDGAR system. AI-powered summaries help interpret lengthy filings by highlighting important sections, such as descriptions of material agreements, financial updates or changes in executive roles. Users can review 8-Ks for event-driven information and refer to other filing types, such as annual and quarterly reports when available, to gain a more complete view of IQVIA’s business and risks.
IQVIA Holdings Inc. appointed Michael J. Fedock as its next Executive Vice President and Chief Financial Officer, effective February 28, 2026, as part of a planned CFO succession. He will succeed Ronald E. Bruehlman, who will retire from the CFO role on that date and become Senior Advisor to the CEO to support a smooth transition.
Mr. Fedock has more than 25 years of healthcare industry experience and has held several senior finance roles at IQVIA since 2016, including Senior Vice President, Financial Planning and Analysis, and CFO roles for key business units. In connection with his promotion, his annual base salary will increase to $750,000, and he will have an annual cash incentive target equal to 100% of base salary, along with eligibility for long-term incentives under IQVIA’s 2017 Incentive and Stock Award Plan and standard executive benefit plans.
Harris Associates L.P. and Harris Associates, Inc. filed an Amendment No. 1 to Schedule 13G reporting beneficial ownership of IQVIA Holdings Inc. common stock. The filing shows an aggregate of 11,753,182 shares, representing 6.8% of the class, with sole voting power over 10,291,782 shares and sole dispositive power over 11,753,182 shares. The Schedule identifies IQVIA's principal executive office at 2400 Ellis Road, Durham, NC.
The statement notes the shares are held in the ordinary course of business and were not acquired to change or influence control of the issuer. The filing is dated as an event on 06/30/2025 and signed on 08/14/2025 by Joseph J. Allessie as General Counsel and Secretary.
IQVIA Holdings Inc. (IQV) filed a Form 4 showing that Senior Vice President & Corporate Controller Keriann Cherofsky sold 549 common shares on 07/23/2025 at $191.53 per share, a transaction valued at roughly $105k. After the sale, her direct ownership stands at 2,910 shares; no derivative securities were involved.
The disposition reduced her direct stake by about 16% (549 of ~3,459 prior shares). While small relative to IQV’s market capitalization and daily trading volume, insider sales can be perceived as a modestly bearish signal because executives possess superior insight into company prospects. No accompanying purchases, option exercises, or material company events were reported in this filing.